Supernus Pharmaceuticals (SUPN) Times Interest Earned (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Times Interest Earned of -$25.04 for Q2 2026, down 144.96% year-over-year from $55.69 in Q2 2025, and down 9267.46% on a QoQ basis from $0.27 in Q4 2025.
Supernus Pharmaceuticals (SUPN) Times Interest Earned (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Times Interest Earned for 16 years, with the latest figure at -$25.04 in Q2 2026.
- Times Interest Earned for Q2 2026 came in at -$25.04, down 144.96% year-over-year; the trailing twelve-month figure through Jun 2026 was $26.76 (down 90.9% YoY), and the FY2025 annual result was -$0.11, down 108.62% from the prior year.
- Times Interest Earned declined to -$25.04 in Q2 2026, from $0.27 in the prior quarter.
- Over five years, Times Interest Earned peaked at $381.73 in Q3 2024 and troughed at -$1309.4 in Q3 2025.
- A 5-year average of -$52.57 and a median of $0.09 in 2022 frame the typical range for Times Interest Earned.
- The widest annual swing landed in 2023, when Times Interest Earned plunged 12858.2%; it then surged 7231.56% in 2024.
- A 5-year view of Times Interest Earned shows it stood at $21.54 in 2022, then sank by 75.83% to $5.21 in 2023, then slumped by 131.09% to -$1.62 in 2024, then surged by 116.87% to $0.27 in 2025, then plunged by 9267.46% to -$25.04 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were -$25.04 in Q2 2026, $0.27 in Q4 2025, and -$1309.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -3.15 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 114.07 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.05 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 52.24 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.20 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -25.04 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.04 |
| Dec 31, 2025 | 0.27 |
| Sep 30, 2025 | -1,309.37 |
| Jun 30, 2025 | 55.69 |
| Mar 31, 2025 | -2.64 |
| Dec 31, 2024 | 5.27 |
| Sep 30, 2024 | 381.73 |
| Jun 30, 2024 | 5.46 |
| Mar 31, 2024 | -0.79 |
| Dec 31, 2023 | -2.12 |
| Jun 30, 2023 | -19.33 |
| Mar 31, 2023 | 1.50 |
| Dec 31, 2022 | 3.31 |
| Sep 30, 2022 | 1.23 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.03 |
| Dec 31, 2021 | 1.03 |
| Sep 30, 2021 | 5.50 |
| Jun 30, 2021 | 6.24 |
| Mar 31, 2021 | 2.17 |